ArticleSignal transduction and targeted therapy2021

Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease.

Qi Sun et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.